Search results for Vunakizumab

Vunakizumab Biosimilar – Anti-IL17A mAb – Research Grade, ProteoGenix, PX-TA1444

Description of Vunakizumab Biosimilar - Anti-IL17A mAb - Research Grade Introduction to Vunakizumab Biosimilar – Anti-IL17A mAb Vunakizumab Biosimilar – Anti-IL17A mAb is a research grade monoclonal antibody (mAb) that targets the cytokine interleukin-17A (IL-17A). This biosimilar is designed to mimic the structure and function of the original Vunakizumab, a fully human mAb developed by Merck for the treatment of autoimmune diseases. In this article, we will delve into the structure, activity, and potential applications of this promising biosimilar. Structure of Vunakizumab Biosimilar – Anti-IL17A mAb Vunakizumab Biosimilar – Anti-IL17A mAb is a recombinant, humanized mAb that is produced in a mammalian cell expression system. It consists of two identical heavy chains and two identical light chains, each with a molecular weight of approximately 150 kDa. The heavy chains are composed of four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chains have two constant domains (CL and CL’) and one variable domain (VL). The VH and VL domains come together to form the antigen-binding site, which is responsible for the specificity of the mAb. Activity of Vunakizumab Biosimilar – Anti-IL17A mAb IL-17A is a pro-inflammatory cytokine that plays a crucial role in the pathogenesis of autoimmune diseases such as psoriasis, rheumatoid arthritis, and inflammatory bowel disease. Vunakizumab Biosimilar – Anti-IL17A mAb binds specifically to IL-17A, preventing it from binding to its receptor and thereby inhibiting its activity. This leads to a decrease in the production of other pro-inflammatory cytokines and chemokines, ultimately reducing inflammation and tissue damage. Applications of Vunakizumab Biosimilar – Anti-IL17A mAb Due to its ability to target IL-17A, Vunakizumab Biosimilar – Anti-IL17A mAb has potential applications in the treatment of various autoimmune diseases. It has been shown to be effective in clinical trials for psoriasis, with a significant reduction in disease severity and improvement in symptoms. In addition, it has also shown promising results in clinical trials for rheumatoid arthritis and ankylosing spondylitis. Furthermore, Vunakizumab Biosimilar – Anti-IL17A mAb has been investigated for its potential in treating other autoimmune diseases such as psoriatic arthritis, Crohn’s disease, and ulcerative colitis. These diseases share a common pathogenesis involving IL-17A, making Vunakizumab Biosimilar – Anti-IL17A mAb a promising therapeutic option. Conclusion In summary, Vunakizumab Biosimilar – Anti-IL17A mAb is a research grade mAb that targets IL-17A, a key cytokine involved in the pathogenesis of various autoimmune diseases. Its structure and activity make it a promising therapeutic option for conditions such as psoriasis, rheumatoid arthritis, and inflammatory bowel disease. With ongoing research and clinical trials, Vunakizumab Biosimilar – Anti-IL17A mAb has the potential to provide new treatment options for patients suffering from these debilitating diseases.

Vunakizumab, Kyinno, KB-1388

Vunakizumab, Abbexa, abx831402

Vunakizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting IL17A, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.

Vunakizumab ELISA Kit, ProteoGenix, KPTX263

Description of Vunakizumab ELISA Kit Introduction Vunakizumab is a humanized monoclonal antibody that has shown promising results in the treatment of various inflammatory diseases. It specifically targets the cytokine interleukin-6 (IL-6), which plays a crucial role in the development of chronic inflammatory conditions. The Vunakizumab ELISA Kit is a specialized tool used to measure the levels of this antibody in biological samples. In this article, we will discuss the structure, activity, and applications of the Vunakizumab ELISA Kit. Structure of Vunakizumab Vunakizumab is a recombinant humanized IgG1 monoclonal antibody, with a molecular weight of approximately 150 kDa. It is composed of two heavy chains and two light chains, connected by disulfide bonds. The antibody has a unique variable region that specifically binds to the IL-6 cytokine, preventing its interaction with its receptor. This binding is essential for the therapeutic activity of Vunakizumab. Activity of Vunakizumab Vunakizumab exerts its therapeutic effects by blocking the activity of IL-6. This cytokine is a key mediator of inflammation and is involved in various pathological processes, such as autoimmune diseases, cancer, and cardiovascular diseases. IL-6 is produced by various cell types, including immune cells, and acts on a wide range of target cells. It promotes the production of acute-phase proteins, stimulates the proliferation of immune cells, and induces the differentiation of B cells into antibody-producing plasma cells. In pathological conditions, such as rheumatoid arthritis and Crohn’s disease, there is an excessive production of IL-6, leading to chronic inflammation and tissue damage. Vunakizumab binds to IL-6 with high affinity, preventing its interaction with its receptor and inhibiting its pro-inflammatory effects. This results in a reduction of inflammation and improved clinical outcomes in patients. Application of Vunakizumab ELISA Kit The Vunakizumab ELISA Kit is a highly sensitive and specific tool used to measure the levels of Vunakizumab in biological samples, such as serum, plasma, and cell culture supernatants. It utilizes a sandwich ELISA method, where the Vunakizumab antibody is immobilized on a solid support and used to capture Vunakizumab present in the sample. The captured Vunakizumab is then detected using a secondary antibody conjugated to an enzyme, which produces a colorimetric signal that can be measured. The Vunakizumab ELISA Kit has various applications in both research and clinical settings. In research, it is used to study the pharmacokinetics and pharmacodynamics of Vunakizumab, as well as to monitor its levels in patients receiving treatment. It can also be used to measure the levels of Vunakizumab in preclinical studies, where the antibody’s efficacy and safety are evaluated. In the clinical setting, the Vunakizumab ELISA Kit is used for patient monitoring, to assess the response to treatment and determine the optimal dosing regimen. It is also used in the diagnosis of inflammatory diseases, where elevated levels of IL-6 and Vunakizumab can indicate disease activity. Additionally, the Vunakizumab ELISA Kit is used in the selection of patients for clinical trials, as it can identify individuals with high levels of IL-6, who are likely to benefit from Vunakizumab treatment. Conclusion In summary, the Vunakizumab ELISA Kit is a valuable tool for the measurement of Vunakizumab levels in biological samples. It plays a crucial role in the research and clinical applications of this promising antibody, which targets the pro-inflammatory cytokine IL-6. With its high sensitivity and specificity, the Vunakizumab ELISA Kit is a reliable method for monitoring Vunakizumab

Vunakizumab ELISA Kit, Abbexa, abx395152

Vunakizumab ELISA Kit is a quantitative ELISA kit for detection of Vunakizumab.Vunakizumab is a recombinant humanized IgGκ monoclonal antibody binds to and neutralises the proinflammatory cytokine interleukin-17A (IL-17A). It was discovered and developed by Jiangsu Hengrui Medicine (China) with the developmental name SHR-1314, for the treatment of autoimmune diseases such as psoriasis, psoriatic arthritis, ankylosing spondylitis, multiple sclerosis and inflammatory arthritis. Atridia Pty. Ltd., which is now a part of Jiangsu Hengrui Medicine, start a phase-I clinical trial in psoriasis (in volunteers) in Australia in August 2016. Atridia completed the phase-I trial in July 2017. A phase-I/II study, which is started from December 2017, is ongoing to assess the safety, tolerability, and pharmacokinetics of SHR-1314 with expanded dose finding in subjects with moderate-to-severe plaque psoriasis.

Vunakizumab Biosimilar - Research Grade, ichor.bio, ICH5995